Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minutePC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Newer options in pet cancer care are real, but they are not equally proven. The American Animal Hospital Association’s 2026 oncology guideline, in a section titled “What’s New in Veterinary Oncology” (published January 1, 2026), describes a fast-moving field and repeatedly asks readers to weigh evidence, cost, risk, and approval or licensing status. In short: some drugs and one local therapy carry FDA approval, several others hold only conditional approval or a USDA conditional license, blood and urine tests cannot replace tissue diagnosis, and cell-based and vaccine approaches are still developing.
The guideline’s overview states that 50% of dogs and approximately 30% of cats over age 10 are affected by cancer, which is why knowing what is established, and for which cancers, matters to so many owners.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Oncology for Veterinary Technicians and Nurses | $82.55 | Buy on Amazon |
| 2 |
|
Withrow and MacEwen's Small Animal Clinical Oncology | $134.99 | Buy on Amazon |
| 3 |
|
Oncology for Veterinary Technicians and Nurses | $90.50 | Buy on Amazon |
| 4 |
|
Veterinary Surgical Oncology | $101.69 | Buy on Amazon |
| 5 |
|
Color Atlas of Canine and Feline Surgical Oncology | $163.94 | Buy on Amazon |
How to read approval status before weighing a new treatment
Regulatory status is the fastest way to tell whether a treatment has been tested to the standard required for a specific use. AAHA separates the two federal agencies involved: the FDA oversees chemical-based drugs, while the USDA regulates biologics such as vaccines and monoclonal antibodies.
| Status | Regulator named in AAHA’s section | What the status means | Limits AAHA notes |
|---|---|---|---|
| Full FDA approval | FDA (chemical-based drugs) | Approved for the uses listed on its label | Extralabel use (use outside label directions) is allowed only for fully approved drugs |
| FDA conditional approval | FDA (chemical-based drugs) | Rests on complete and acceptable safety plus a “reasonable expectation of effectiveness” when used according to the label; studies toward full approval may be ongoing | AAHA states that extralabel use of conditionally approved drugs is illegal |
| USDA conditional license | USDA (biologics such as vaccines and monoclonal antibodies) | Conditional licensure of a biologic; full licensure studies may be ongoing | Not stated in the AAHA section |
| Investigational (clinical study) | Not stated in the AAHA section | Not an approved treatment; evidence is still being generated | Eligibility is set by each study |
Statuses are a snapshot. The AAHA descriptions below reflect the January 2026 guideline, and approvals and licenses can change, so confirm the current status in the FDA or USDA record and on the product label before making any decision.
#1 Best Overall
Blood and urine tests: what they can and cannot do
AAHA’s central warning about screening tests is direct:
“At this time, no blood or urine test can conclusively rule in or rule out cancer in a veterinary patient, so these tests must be used with caution to avoid providing a false sense of security or causing undue alarm.”
American Animal Hospital Association, 2026 oncology guideline
The guideline identifies two categories of emerging test. It states that evidence is currently insufficient to conclude that either category meaningfully improves outcomes in animals, and that a product being on the market does not by itself establish accuracy or patient benefit.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Fix the driver behind crashes, sound loss and screen glitches3Clear out junk files and repair common Windows errorsLiquid biopsies
Liquid biopsies use blood or urine biomarkers and may be intended for diagnosis, screening, or monitoring. These are different claims. A test validated to monitor a known cancer answers a different question from one marketed to screen healthy animals, so the first question to ask is which use is being proposed.
Rank #2
Precision-medicine profiles
These profiles use blood or tumor samples to characterize tumor biology and identify treatments a tumor may be more susceptible to, based on genomic features. The output is a treatment hypothesis rather than a diagnosis. Ask what the report would change in your pet’s plan and what evidence links the profile to the drug being suggested.
Why prevalence changes what a positive result means
Sensitivity is the share of cancer cases a test flags, and specificity is the share of cancer-free animals it clears. Positive predictive value (PPV) is the chance that a positive result reflects real cancer. Negative predictive value (NPV) is the chance that a negative result is truly cancer-free. Both depend heavily on how common the cancer is in the animals being tested, not only on the test’s sensitivity and specificity.
The table below uses a hypothetical test with 90% sensitivity and 90% specificity. The numbers are arithmetic to show the pattern; they are not data for any product.
Recommended Free Tools
| Cancer prevalence in the tested group | Positive predictive value | Negative predictive value |
|---|---|---|
| 1% | about 8% | about 99.9% |
| 5% | about 32% | about 99.4% |
| 20% | about 69% | about 97.3% |
At 1% prevalence, roughly 9 in 10 positive results would be false alarms under these assumptions. A negative result is reassuring in every row, but a positive result is only as meaningful as the disease’s prevalence in the population tested.
Tissue diagnosis and staging still anchor treatment
Newer tests do not change the core sequence AAHA describes for treatment decisions:
- Cytologic or histopathologic diagnosis, which establishes what the tumor is.
- Grade and stage where appropriate, which describe how aggressive the tumor looks and how far it has extended.
- Staging diagnostics, which look for spread that would change the treatment plan.
Approved and conditionally approved drugs
The following descriptions come from AAHA’s 2026 section. Each describes a drug’s status and known adverse effects, not a recommendation for an individual animal.
Rabacfosadine for canine lymphoma
AAHA describes rabacfosadine as fully FDA-approved for canine lymphoma. It is given by intravenous (IV) infusion. The guideline reports gastrointestinal upset and neutropenia (a low neutrophil count, which raises infection risk) as common adverse effects, with cutaneous reactions and pulmonary fibrosis less common.
Verdinexor for canine lymphoma
Verdinexor is FDA conditionally approved for canine lymphoma. It is an oral selective inhibitor of nuclear export, meaning it blocks one pathway cells use to move certain molecules out of the nucleus. AAHA lists anorexia, vomiting, diarrhea, and lethargy among its adverse effects and notes that studies toward full approval are ongoing.
Crofelemer-CA1 for chemotherapy-induced diarrhea
Crofelemer-CA1 is conditionally approved for managing chemotherapy-induced diarrhea in dogs. It treats a side effect of chemotherapy rather than the tumor itself, so it belongs in supportive care rather than in cancer treatment.
Gilvetmab for mast cell tumors and melanoma
Gilvetmab is a canine anti-PD-1 monoclonal antibody. PD-1 is a protein that can help tumor cells evade immune attack, and blocking it is an immune-based approach. AAHA says gilvetmab holds a USDA conditional license for dogs with mast cell tumors or melanomas and is available through veterinary oncology specialists. Full licensure studies are ongoing.
Rank #4
Local treatments for selected tumors
Tigilanol tiglate for selected mast cell tumors
AAHA describes tigilanol tiglate as an FDA-approved intratumoral therapy, injected into the tumor, for selected nonmetastatic canine mast cell tumors. “Nonmetastatic” means the cancer has not spread to distant sites. Its approved use is restricted by tumor location, tumor size, and total dose. The guideline says wound healing is usually complete within 4–8 weeks.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Electrochemotherapy
Electrochemotherapy is a developing local treatment. An electrical field increases the permeability of tumor cells, which may enhance the effect of chemotherapy. It requires a specialized clinical unit and is not a home treatment.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Developing cell-based and vaccine approaches
AAHA groups these approaches as developing and says more research is needed before they can be considered established.
Cell therapies
The guideline describes adoptive cell therapy, ELIAS cancer immunotherapy, and CAR T-cell therapy as developing approaches. Evidence for each is still being built, and most owners will encounter them only through a study or a specialist referral.
Patient-specific (autologous) vaccines
These vaccines are made from the animal’s own tumor tissue. AAHA says peer-reviewed evidence for autologous vaccines is limited. If one is offered, ask whether it is part of a documented study or a clinical service, and ask for the published data behind it.
Best Value
Clinical trials and investigational options
Penn Vet, the veterinary school of the University of Pennsylvania, lists oncology studies on its site. As of early October 2026, its listings include:
- A study dated September 29, 2026, evaluating FLASH proton radiation, alone or with gilvetmab, for canine glioma.
- A study of proton FLASH radiation for naturally occurring canine extremity sarcoma.
- An iNKT cell therapy study for metastatic osteosarcoma.
- A targeted PSMA-ligand theranostic approach for canine prostate cancer.
These are investigational. None is an established standard of care. Recruitment and eligibility criteria change, so check the live study record or ask a veterinary oncologist rather than assuming a pet qualifies from a listing.
Quality of life and supportive care
AAHA treats supportive care as part of cancer treatment. It emphasizes nutritional and pain assessment throughout treatment, not only at the start, and states that chemotherapy’s primary goal is to maintain the best possible quality of life while managing cancer. That framing is the right lens for the newer options: an expected benefit has to be weighed against adverse effects, and against the visits, travel, and monitoring a treatment requires.
Questions to take to your veterinarian
AAHA frames these decisions as individualized, made with the primary-care veterinarian and, when appropriate, a veterinary oncologist. The questions below track the comparison points the guideline uses for tests and therapies.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Clear out junk files and repair common Windows errorsFree Scan →Quick Recap
- Is the test proposed for screening, diagnosis, or monitoring, and what sample does it use?
- How common is this cancer in animals like mine, and what would a positive or negative result mean at that prevalence?
- Has the tumor type, grade, and stage been established by cytology or histopathology, plus staging?
- Is the treatment fully approved, conditionally approved, USDA-licensed, or investigational, and for which cancer type?
- What route, setting, and specialist access does it require, and what will it cost?
- Which adverse effects are expected, and what is the plan for nutrition and pain?
- What evidence shows the option improves outcomes for animals, rather than only detecting disease or changing a marker?
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
